Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

ZIP14通过调控P38 MAPK通路影响宫颈癌细胞的增殖、凋亡和迁移

卷 24, 期 8, 2024

发表于: 21 November, 2023

页: [779 - 790] 页: 12

弟呕挨: 10.2174/0115680096250711231024063841

价格: $65

conference banner
摘要

背景：子宫颈癌(CC)仍然是一个主要的公共卫生问题，也是全世界女性死亡的主要原因。了解其发病机制的分子基础对于开发新的治疗策略至关重要。在这项研究中，我们旨在剖析一个特定的分子ZIP14在CC的发生和发展中的作用。 方法：我们使用基因表达Omnibus来鉴定靶基因，而使用KEGG来描述cc相关途径。分别使用CCK8、Transwell和流式细胞术评估CC细胞的增殖、迁移和凋亡水平。目的基因对CC细胞体内肿瘤发生的影响采用皮下肿瘤发生试验。 结果：在CC样品中发现ZIP14 (SLC39A14)表达过低。我们的KEGG通路分析揭示了P38丝裂原活化蛋白激酶(MAPK)通路在CC发病机制中的潜在参与。HeLa和Caski细胞中ZIP14过表达增加p38磷酸化，抑制细胞生长和迁移，促进细胞凋亡。相反，ZIP14敲低产生相反的效果。重要的是，ZIP14过表达诱导的生物效应可以被p38 MAPK通路抑制剂SB203580抵消。体内实验进一步证实了ZIP14对CC细胞迁移的影响。 结论：我们的研究首次阐明了ZIP14在CC发病机制中的关键作用，揭示了其通过激活p38 MAPK信号通路的抑制作用。这一发现不仅提供了对CC分子基础的更深入了解，而且突出了ZIP14作为一个有前途的治疗靶点。由于ZIP14具有显著的治疗干预潜力，我们的研究结果为进一步的研究奠定了坚实的基础，并为探索宫颈癌的新治疗方式铺平了道路。

关键词: 宫颈癌，ZIP14, P38 MAPK, GEO，发病机制，细胞凋亡，水平。

Next »
图形摘要

[1]
Fang, J.; Zhang, H.; Jin, S. Epigenetics and cervical cancer: From pathogenesis to therapy. Tumour Biol., 2014, 35(6), 5083-5093.
[http://dx.doi.org/10.1007/s13277-014-1737-z] [PMID: 24554414]
[2]
Xiong, H.; Wang, N.; Chen, H.; Zhang, M.; Lin, Q. MicroRNA199a/b5p inhibits endometrial cancer cell metastasis and invasion by targeting FAM83B in the epithelialtomesenchymal transition signaling pathway. Mol Med Rep., 2021, 23(5), 304.
[3]
Cohen, P.A.; Jhingran, A.; Oaknin, A.; Denny, L. Cervical cancer. Lancet, 2019, 393(10167), 169-182.
[http://dx.doi.org/10.1016/S0140-6736(18)32470-X] [PMID: 30638582]
[4]
Xie, Y.; Wang, J.; Zhao, X.; Zhou, X.; Nie, X.; Li, C.; Huang, F.; Yuan, H. Higher serum zinc levels may reduce the risk of cervical cancer in Asian women: A meta-analysis. J. Int. Med. Res., 2018, 46(12), 4898-4906.
[http://dx.doi.org/10.1177/0300060518805600] [PMID: 30370809]
[5]
Lim, S.S.; Vos, T.; Flaxman, A.D.; Danaei, G.; Shibuya, K.; Adair-Rohani, H.; AlMazroa, M.A.; Amann, M.; Anderson, H.R.; Andrews, K.G.; Aryee, M.; Atkinson, C.; Bacchus, L.J.; Bahalim, A.N.; Balakrishnan, K.; Balmes, J.; Barker-Collo, S.; Baxter, A.; Bell, M.L.; Blore, J.D.; Blyth, F.; Bonner, C.; Borges, G.; Bourne, R.; Boussinesq, M.; Brauer, M.; Brooks, P.; Bruce, N.G.; Brunekreef, B.; Bryan-Hancock, C.; Bucello, C.; Buchbinder, R.; Bull, F.; Burnett, R.T.; Byers, T.E.; Calabria, B.; Carapetis, J.; Carnahan, E.; Chafe, Z.; Charlson, F.; Chen, H.; Chen, J.S.; Cheng, A.T-A.; Child, J.C.; Cohen, A.; Colson, K.E.; Cowie, B.C.; Darby, S.; Darling, S.; Davis, A.; Degenhardt, L.; Dentener, F.; Des Jarlais, D.C.; Devries, K.; Dherani, M.; Ding, E.L.; Dorsey, E.R.; Driscoll, T.; Edmond, K.; Ali, S.E.; Engell, R.E.; Erwin, P.J.; Fahimi, S.; Falder, G.; Farzadfar, F.; Ferrari, A.; Finucane, M.M.; Flaxman, S.; Fowkes, F.G.R.; Freedman, G.; Freeman, M.K.; Gakidou, E.; Ghosh, S.; Giovannucci, E.; Gmel, G.; Graham, K.; Grainger, R.; Grant, B.; Gunnell, D.; Gutierrez, H.R.; Hall, W.; Hoek, H.W.; Hogan, A.; Hosgood, H.D., III; Hoy, D.; Hu, H.; Hubbell, B.J.; Hutchings, S.J.; Ibeanusi, S.E.; Jacklyn, G.L.; Jasrasaria, R.; Jonas, J.B.; Kan, H.; Kanis, J.A.; Kassebaum, N.; Kawakami, N.; Khang, Y-H.; Khatibzadeh, S.; Khoo, J-P.; Kok, C.; Laden, F.; Lalloo, R.; Lan, Q.; Lathlean, T.; Leasher, J.L.; Leigh, J.; Li, Y.; Lin, J.K.; Lipshultz, S.E.; London, S.; Lozano, R.; Lu, Y.; Mak, J.; Malekzadeh, R.; Mallinger, L.; Marcenes, W.; March, L.; Marks, R.; Martin, R.; McGale, P.; McGrath, J.; Mehta, S.; Memish, Z.A.; Mensah, G.A.; Merriman, T.R.; Micha, R.; Michaud, C.; Mishra, V.; Hanafiah, K.M.; Mokdad, A.A.; Morawska, L.; Mozaffarian, D.; Murphy, T.; Naghavi, M.; Neal, B.; Nelson, P.K.; Nolla, J.M.; Norman, R.; Olives, C.; Omer, S.B.; Orchard, J.; Osborne, R.; Ostro, B.; Page, A.; Pandey, K.D.; Parry, C.D.H.; Passmore, E.; Patra, J.; Pearce, N.; Pelizzari, P.M.; Petzold, M.; Phillips, M.R.; Pope, D.; Pope, C.A., III; Powles, J.; Rao, M.; Razavi, H.; Rehfuess, E.A.; Rehm, J.T.; Ritz, B.; Rivara, F.P.; Roberts, T.; Robinson, C.; Rodriguez-Portales, J.A.; Romieu, I.; Room, R.; Rosenfeld, L.C.; Roy, A.; Rushton, L.; Salomon, J.A.; Sampson, U.; Sanchez-Riera, L.; Sanman, E.; Sapkota, A.; Seedat, S.; Shi, P.; Shield, K.; Shivakoti, R.; Singh, G.M.; Sleet, D.A.; Smith, E.; Smith, K.R.; Stapelberg, N.J.C.; Steenland, K.; Stöckl, H.; Stovner, L.J.; Straif, K.; Straney, L.; Thurston, G.D.; Tran, J.H.; Van Dingenen, R.; van Donkelaar, A.; Veerman, J.L.; Vijayakumar, L.; Weintraub, R.; Weissman, M.M.; White, R.A.; Whiteford, H.; Wiersma, S.T.; Wilkinson, J.D.; Williams, H.C.; Williams, W.; Wilson, N.; Woolf, A.D.; Yip, P.; Zielinski, J.M.; Lopez, A.D.; Murray, C.J.L.; Ezzati, M. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859), 2224-2260.
[http://dx.doi.org/10.1016/S0140-6736(12)61766-8] [PMID: 23245609]
[6]
Huang, Z.L.; Dufner-Beattie, J.; Andrews, G.K. Expression and regulation of SLC39A family zinc transporters in the developing mouse intestine. Dev. Biol., 2006, 295(2), 571-579.
[http://dx.doi.org/10.1016/j.ydbio.2006.03.045] [PMID: 16682017]
[7]
Bowers, K.; Srai, S.K.S. The trafficking of metal ion transporters of the Zrt- and Irt-like protein family. Traffic, 2018, 19(11), 813-822.
[http://dx.doi.org/10.1111/tra.12602] [PMID: 29952128]
[8]
Anderson, K.J.; Cormier, R.T.; Scott, P.M. Role of ion channels in gastrointestinal cancer. World J. Gastroenterol., 2019, 25(38), 5732-5772.
[http://dx.doi.org/10.3748/wjg.v25.i38.5732] [PMID: 31636470]
[9]
Jenkitkasemwong, S.; Akinyode, A.; Paulus, E.; Weiskirchen, R.; Hojyo, S.; Fukada, T.; Giraldo, G.; Schrier, J.; Garcia, A.; Janus, C.; Giasson, B.; Knutson, M.D. SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. Proc. Natl. Acad. Sci., 2018, 115(8), E1769-E1778.
[http://dx.doi.org/10.1073/pnas.1720739115] [PMID: 29437953]
[10]
Balint, B.; Bhatia, K.P. SLC39A14 mutations expand the spectrum of manganese transporter defects causing parkinsonism-dystonia. Mov. Disord., 2016, 31(11), 1630.
[http://dx.doi.org/10.1002/mds.26821] [PMID: 27739105]
[11]
Liu, Y.; Li, L.; Liu, Y.; Geng, P.; Li, G.; Yang, Y.; Song, H. RECK inhibits cervical cancer cell migration and invasion by promoting p53 signaling pathway. J. Cell. Biochem., 2018, 119(4), 3058-3066.
[http://dx.doi.org/10.1002/jcb.26441] [PMID: 29064588]
[12]
Rodrigues, C.; Joy, L.R.; Sachithanandan, S.P.; Krishna, S. Notch signalling in cervical cancer. Exp. Cell Res., 2019, 385(2), 111682.
[http://dx.doi.org/10.1016/j.yexcr.2019.111682] [PMID: 31634483]
[13]
Ramos-Solano, M.; Alvarez-Zavala, M.; Garcia-Castro, B.; Jave-Suarez, L. F.; Aguilar-Lemarroy, A. Wnt signalling pathway and cervical cancer. Rev Med Inst Mex Seguro Soc, 2015, 53(S2), S218-S224.
[14]
Che, Y.; Li, Y.; Zheng, F. TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling. Cancer Lett, 2019, 452, 1-13.
[http://dx.doi.org/10.1016/j.canlet.2019.03.017]
[15]
Yuan, Z.; Liang, Z.; Yi, J. Koumine promotes ROS production to suppress hepatocellular carcinoma cell proliferation via NF-kappaB and ERK/p38 MAPK signaling. Biomolecules, 2019, 9(10), 559.
[16]
Cui, D.; Xiao, J.; Zhou, Y.; Zhou, X.; Liu, Y.; Peng, Y.; Yu, Y.; Li, H.; Zhou, X.; Yuan, Q.; Wan, M.; Zheng, L. Epiregulin enhances odontoblastic differentiation of dental pulp stem cells via activating MAPK signalling pathway. Cell Prolif., 2019, 52(6), e12680.
[http://dx.doi.org/10.1111/cpr.12680] [PMID: 31454111]
[17]
Liu, F.; Chang, L.; Hu, J. Activating transcription factor 6 regulated cell growth, migration and inhibiteds cell apoptosis and autophagy via MAPK pathway in cervical cancer. J Reprod Immunol, 2020, 139, 103120.
[http://dx.doi.org/10.1016/j.jri.2020.103120]
[18]
Gan, L.; Chen, Y.; Liu, H.; Ju, W.H. Long non-coding RNA ZEB1-antisense 1 affects cell migration and invasion of cervical cancer by regulating epithelial-mesenchymal transition via the p38MAPK signaling pathway. Gynecol. Obstet. Invest., 2019, 84(2), 136-144.
[http://dx.doi.org/10.1159/000493265] [PMID: 30253398]
[19]
Zhu, J.; Zheng, Y.; Zhang, H.; Liu, Y.; Sun, H.; Zhang, P. Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway. Am. J. Transl. Res., 2019, 11(6), 3862-3878.
[PMID: 31312395]
[20]
Zhang, A.; Lakshmanan, J.; Motameni, A.; Harbrecht, B.G. MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA, p38 MAPK, c-Jun, and GSK3 signaling. Mol. Cell. Biochem., 2018, 441(1-2), 89-98.
[http://dx.doi.org/10.1007/s11010-017-3176-9] [PMID: 28887744]
[21]
Moriguchi, M.; Watanabe, T.; Kadota, A.; Fujimuro, M. Capsaicin induces apoptosis in KSHV-positive primary effusion lymphoma by suppressing ERK and p38 MAPK signaling and IL-6 expression. Front Oncol., 2019, 9, 83.
[http://dx.doi.org/10.3389/fonc.2019.00083]
[22]
Kim, M.S.; Lee, E.J.; Kim, H.R.; Moon, A. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res., 2003, 63(17), 5454-5461.
[PMID: 14500381]
[23]
Nimmanon, T.; Ziliotto, S.; Morris, S.; Flanagan, L.; Taylor, K.M. Phosphorylation of zinc channel ZIP7 drives MAPK, PI3K and mTOR growth and proliferation signalling. Metallomics, 2017, 9(5), 471-481.
[http://dx.doi.org/10.1039/C6MT00286B] [PMID: 28205653]
[24]
Zhu, B.; Huo, R.; Zhi, Q. Increased expression of zinc transporter ZIP4, ZIP11, ZnT1, and ZnT6 predicts poor prognosis in pancreatic cancer. J Trace Elem Med Biol., 2021, 65, 126734.
[http://dx.doi.org/10.1016/j.jtemb.2021.126734]
[25]
Feng, M.; Wang, Y.; Chen, K.; Bian, Z.; Jinfang Wu; Gao, Q. IL-17A promotes the migration and invasiveness of cervical cancer cells by coordinately activating MMPs expression via the p38/NF-κB signal pathway. PLoS One, 2014, 9(9), e108502.
[http://dx.doi.org/10.1371/journal.pone.0108502] [PMID: 25250801]
[26]
Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001, 25(4), 402-408.
[http://dx.doi.org/10.1006/meth.2001.1262] [PMID: 11846609]
[27]
Thomas, P.; Pang, Y.; Dong, J. Membrane androgen receptor characteristics of human ZIP9 (SLC39A) zinc transporter in prostate cancer cells: Androgen-specific activation and involvement of an inhibitory G protein in zinc and MAP kinase signaling. Mol Cell Endocrinol, 2017, 23
[http://dx.doi.org/10.1016/j.mce.2017.02.025]
[28]
Liu, L.; Yang, J.; Wang, C. Analysis of the prognostic significance of solute carrier (SLC) family 39 genes in breast cancer. Biosci Rep, 2020, 40(8), 2020.
[http://dx.doi.org/10.1042/BSR20200764]
[29]
Shakri, A.R.; Zhong, T.J.; Ma, W. Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia. Cancers, 2019, 12(1), 3.
[http://dx.doi.org/10.3390/cancers12010003]
[30]
Ziliotto, S.; Gee, J.M.W.; Ellis, I.O.; Green, A.R.; Finlay, P.; Gobbato, A.; Taylor, K.M. Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. Metallomics, 2019, 11(9), 1579-1592.
[http://dx.doi.org/10.1039/c9mt00136k] [PMID: 31483418]
[31]
Mei, Z.; Yan, P.; Wang, Y.; Liu, S.; He, F. Knockdown of zinc transporter ZIP8 expression inhibits neuroblastoma progression and metastasis in vitro. Mol. Med. Rep., 2018, 18(1), 477-485.
[http://dx.doi.org/10.3892/mmr.2018.8944] [PMID: 29749445]
[32]
Franklin, R.B.; Levy, B.A.; Zou, J.; Hanna, N.; Desouki, M.M.; Bagasra, O.; Johnson, L.A.; Costello, L.C. ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer. J. Gastrointest. Cancer, 2012, 43(2), 249-257.
[http://dx.doi.org/10.1007/s12029-011-9269-x] [PMID: 21373779]
[33]
Liu, Y.; Zhu, X.; Zhu, J.; Liao, S.; Tang, Q.; Liu, K.; Guan, X.; Zhang, J.; Feng, Z. Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol. Rep., 2007, 18(4), 943-951.
[http://dx.doi.org/10.3892/or.18.4.943] [PMID: 17786358]
[34]
Taylor, K.M.; Morgan, H.E.; Johnson, A.; Nicholson, R.I. Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett., 2005, 579(2), 427-432.
[http://dx.doi.org/10.1016/j.febslet.2004.12.006] [PMID: 15642354]
[35]
Shakri, A.R.; James Zhong, T.; Ma, W.; Coker, C.; Hegde, R.; Scholze, H.; Chin, V.; Szabolcs, M.; Hibshoosh, H.; Tanji, K.; Baer, R.; Kumar Biswas, A.; Acharyya, S. Aberrant Zip14 expression in muscle is associated with cachexia in a Bard1 -deficient mouse model of breast cancer metastasis. Cancer Med., 2020, 9(18), 6766-6775.
[http://dx.doi.org/10.1002/cam4.3242] [PMID: 32730698]
[36]
Gaundar, S.S.; Bendall, L.J. The potential and limitations of p38MAPK as a drug target for the treatment of hematological malignancies. Curr. Drug Targets, 2010, 11(7), 823-833.
[http://dx.doi.org/10.2174/138945010791320854] [PMID: 20370645]
[37]
Huang, S.W.; Chyuan, I.T.; Shiue, C.; Yu, M.C.; Hsu, Y.F.; Hsu, M.J. Lovastatin-mediated MCF-7 cancer cell death involves LKB1-AMPK-p38MAPK-p53-survivin signalling cascade. J. Cell. Mol. Med., 2020, 24(2), 1822-1836.
[http://dx.doi.org/10.1111/jcmm.14879] [PMID: 31821701]
[38]
Chou, R.H.; Hsieh, S.C.; Yu, Y.L.; Huang, M.H.; Huang, Y.C.; Hsieh, Y.H. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway. PLoS One, 2013, 8(8), e71983.
[http://dx.doi.org/10.1371/journal.pone.0071983] [PMID: 23940799]

Rights & Permissions Print Cite
Article Metrics
32
3
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy